- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01540786
An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics
An Exploratory Study to Evaluate Bladder Contractions in the Storage Phase (Non Voiding Activities) and Related Bladder Sensation in Healthy Females and Untreated Females With Overactive Bladder ("OAB") Using High Resolution and Conventional Urodynamics
This study aims to identify differences in bladder contractions during the storage phase (non voiding activities) between OAB subjects and healthy subjects, using high resolution urodynamics.
The study is divided into two parts:
- PART 1: Consists of 5 females with overactive bladder
- PART 2: Consists of 25 females with overactive bladder and 15 healthy females
Part 1 subjects will be enrolled followed by part 2 subjects. The data from part 1 subjects will be reviewed and analysed by a group of experts before starting the second part (part 2) of the study.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The subjects will complete a total of 2 visits and a follow up telephone call (or visit at the investigator's discretion).
Upon meeting eligibility criteria subjects will be screened and complete visit at hospital (Visit 1). They will then be asked to complete procedures such micturition diary, questionnaires and if applicable discontinued their ongoing OAB medication. Upon confirmation of eligibility criteria subjects will then be enrolled and complete visit 2 within 6 to 31 days post V1. At Visit 2 subjects will complete high resolution urodynamic assessment followed by the conventional urodynamic assessment. The visit will take approximately half a day. Safety follow up phone call (or visit at investigator's discretion) will take place 4 to 6 days post visit 2.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Maastricht, Olanda, 6202
- Maastricht University Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
OAB Subjects
- Has history of signs and symptoms of OAB including urinary frequency, urgency or urge incontinence for greater than or equal to 3 months
At enrolment visit (V2) the subjects must have:
- At least 1 episode of urgency with or without incontinence in the last 3-day micturition diary
- Frequency of micturition greater than or equal to 8 per 24 hours period during the 3-day micturition diary period
- At the screening visit, the subject should be either naïve to OAB treatment (e.g no prior history of medications to treat lower urinary tract symptoms (LUTS), including OAB) or currently on treatment for LUTS (including OAB) and is willing to undergo a washout period for 3 weeks
Main Exclusion criteria:
Healthy subjects
- History of lower urinary tract symptoms (LUTS), including OAB
- History of stress urinary incontinence, urethral sphincter incompetence and neurogenic detrusor overactivity
- History of signs or symptoms suggestive of urinary tract infection (confirmed by positive urine analysis)
- History of bladder outlet obstruction (not including detrusor-overactivity) for example bladder/vesicouterine pro-lapse (> grade II) or chronic obstruction
- History of urinary tract surgery less than or equal to 6 months prior to screening
- Has an indwelling catheter or permanent catheter fitted
- History of pelvic area radiotherapy treatment
- Uncontrolled diabetes mellitus
- History of fibromyalgia
- Pregnant or intends to become pregnant during the study or sexually active, of childbearing potential and is unwilling to utilize a reliable method of birth control (note: reliable methods are contraceptive pills of combination type, hormonal implants, injectable contraceptives, sexual abstinence or vasectomized partner)
- Pregnancy within 6 months before screening or breast feeding within 3 months before screening
- History of a positive hepatitis A, B surface antigen, hepatitis C antibody or HIV test result.
- Any use of drugs of abuse within 3 months prior to screening visit.
- History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to screening visit
- History of drinking more than 14 units of alcohol per week (1 unit = 10 g pure alcohol = 250 ml of beer (5%) or 35 ml of spirits (35%) or 100 ml of wine (12%) within 3 months prior to screening visit
- Is currently receiving or has a history of treatment with alpha blockers, beta receptor blockers or agonists, botulinum toxin (less than 12 months), resiniferatoxin or pelvic floor muscle relaxants less than or equal to 9 months prior to screening
Main exclusion criteria OAB subjects
- Refer to healthy subjects exclusion criteria number 2 to 16
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Part 1: OAB subjects
|
|
|
Sperimentale: Part 2: Healthy subjects
|
|
|
Sperimentale: Part 2: OAB subjects
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Identify objective parameters to characterize Non Voiding Activity (NVA) in healthy and OAB subjects using high resolution urodynamic assessment
Lasso di tempo: During the High resolution urodynamics (Day 1)
|
NVA is defined as changes of pressure in the bladder lumen.
These changes are measured as detrusor pressure (Pdet) calculated from substraction of intra-abdominal pressure (Pabd) from intra-vesical pressure (Pves).
All Pdet with an amplitude of at least 1cm of water, frequency below 0.2 Hz and pulse duration between 5 and 60 seconds qualify as NVA.
|
During the High resolution urodynamics (Day 1)
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Identify NVA in healthy and OAB subjects using conventional urodynamic assessment
Lasso di tempo: During High resolution and conventional urodynamic (Day 1) assessments
|
During High resolution and conventional urodynamic (Day 1) assessments
|
|
Assess the subjects bladder sensations measured by visual analogue scale (VAS) and 5-points categorical scale (Appendix 8 & 7) during the high resolution urodynamic and conventional assessments
Lasso di tempo: During High resolution and conventional urodynamic assessments (Day 1)
|
During High resolution and conventional urodynamic assessments (Day 1)
|
|
Assess the correlation between NVA and subjects bladder sensations
Lasso di tempo: During High resolution and conventional urodynamic assessments (Day 1)
|
During High resolution and conventional urodynamic assessments (Day 1)
|
|
Explore NVA in a subgroup of subjects defined by the severity of OAB symptoms collected as background information (3-days bladder diary)
Lasso di tempo: During High resolution and conventional urodynamic assessments (Day 1)
|
During High resolution and conventional urodynamic assessments (Day 1)
|
|
Illustrate the amount of NVA detected with high resolution urodynamic test methodology compared to NVA detected with conventional urodynamic assessments
Lasso di tempo: During High resolution and conventional urodynamic assessments (Day 1)
|
During High resolution and conventional urodynamic assessments (Day 1)
|
|
Assess symptoms severity, bother and its impact on quality of life using: OAB-Q short form and Urogenital Distress Inventory (UDI-6) questionnaires and a 3-Day micturition bladder diary as background information to characterize the study population
Lasso di tempo: During High resolution and conventional urodynamic assessments (Day 1)
|
During High resolution and conventional urodynamic assessments (Day 1)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Cattedra di studio: Clinical Study Manager, Astellas Pharma Europe Ltd.
- Investigatore principale: Principal Investigator, Maastricht University Medical Center, Maastricht
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 905-EC-010
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .